甲状腺微粒体抗体

摘要： 目的:探讨血清甲状腺球蛋白抗体(TGAb)、甲状腺微粒体抗体(TMAb)、甲状腺过氧化物酶抗体(TPOAb)在自身免疫性甲状腺病中的诊断价值。方法:选取2019年1月-2020年1月某院收治的169例自身免疫性甲状腺病患者作为观察组,选取同期85例健康体检者作为对照组,检测两组血清TGAb、TMAb及TPOAb水平并对其结果进行分析。结果:研究组甲状腺功能亢进、甲状腺功能减退、单纯甲状腺肿大患者的TGAb、TMAb、TPOAb阳性率、检出水平均高于对照组(P<0.05);血清TGAb、TMAb、TPOAb与甲状腺功能亢进呈负相关(r=-4.525、-0.521、-0.422,P<0.05),与甲状腺功能减退、单纯甲状腺肿大呈正相关(r=0.518、0.680、0.469、0.529、0.475、0.614,P<0.05)。结论:自身免疫性甲状腺病患者血清TGAb、TMAb、TPOAb水平明显升高,并和疾病密切相关,临床中对血清甲状腺自身抗体进行检测有利于确诊甲状腺疾病类型给予有效治疗。

摘要： 患者女,54岁,因“20+d前超声检查发现甲状腺左侧叶下份结节”入院。3年前因“子宫颈低分化腺癌伴神经内分泌癌”行子宫附件全切术+盆腔淋巴结清扫术。实验室检查:甲状腺微粒体抗体427.9 U/ml、甲状腺球蛋白抗体>500.0 U/ml、甲状腺过氧化物酶抗体>1300.0 U/ml。超声检查:甲状腺左侧叶下份可见大小约1.1 cm×0.8 cm的低回声结节,形态不规则,边界欠清楚;CDFI示周边可探及条状血流信号。见图1。超声提示:甲状腺左侧叶实性结节,TI-RADS 4C类。

摘要： 目的 观察隔姜灸联合中药对亚急性甲状腺炎(SAT)患者血清25羟维生素D[25-(OH)D3]、促生长素(ghrelin)及甲状腺球蛋白抗体(TgAb)、甲状腺微粒体抗体(TMAb)表达水平的影响.方法 将130例SAT患者作为研究对象,随机分为观察组44例,对照A组43例,对照B组43例.3组均予口服甲泼尼龙片,于此基础上,对照A组予以清热消瘿汤口服,对照B组予以隔姜灸,观察组予以隔姜灸联合清热消瘿汤口服.观察3组临床疗效、不良反应发生率及治疗前后血清甲状腺生化指标[超敏促甲状腺激素(TSH)、三碘甲状腺原氨酸(T3)、甲状腺素(T4)]、血沉(ESR)、25-(OH)D3、ghrelin及TgAb、TMAb水平.结果 观察组治愈率高于对照A组、对照B组(P0.05).结论 隔姜灸联合中药治疗SAT,可明显促进患者症状、体征恢复,改善甲状腺功能,调节机体免疫及炎性反应表达.

摘要： 目的检测桥本甲状腺炎(hashimoto thyroiditis, HT)患者和健康体检者血浆中B细胞活化因子(B-cell activating factor, BAFF)和白介素21(IL-21)表达水平,探讨二者在HT发病机制中的作用。方法选取2019年12月—2020年6月蚌埠医学院第一附属医院内分泌门诊就诊HT患者82例作为观察组(HT组),并根据甲状腺功能将HT组分成NHT组(甲状腺功能正常,39例)和SHT组(甲状腺功能减退或亚临床甲减,43例),选取同期健康体检者51例作为对照组(NC组)。收集受试者外周静脉血血浆,酶联免疫吸附实验(ELISA)检测研究对象血浆BAFF、IL-21,化学发光免疫法检测甲状腺功能及相关抗体等指标。使用SPSS 24.0统计学软件对数据进行详细分析。结果 HT组患者血浆中BAFF、IL-21表达水平较NC组明显上调(均P<0.05)。HT患者血浆中BAFF与甲状腺球蛋白抗体(TgAb)、甲状腺微粒体抗体(TMAb)水平呈正相关(r=0.444、0.401,均P<0.05),IL-21与TgAb、TMAb水平呈正相关(r=0.451、0.451,均P<0.05),BAFF与IL-21呈正相关(r=0.324,P<0.05),BAFF与总甲状腺素(TT4)呈负相关(r=-0.214,P<0.05)。BAFF和IL-21(AUC=0.896)联合诊断HT较BAFF(AUC=0.862)、IL-21(AUC=0.809)单独诊断价值更高。结论 BAFF与IL-21水平与HT病变有关,与TgAb、TMAb水平密切相关,可能参与HT的发生发展过程。

摘要： 目的 研究甲状腺癌患者血清甲状腺球蛋白抗体(TgAb)、甲状腺微粒体抗体(TMAb)及促甲状腺激素(TSH)的水平及意义.方法 选择接受治疗的甲状腺结节患者作为研究对象,根据诊断结果 分为A组(甲状腺癌)和B组(良性甲状腺结节)各60例.同期进行体检的健康人60例作为对照组.检测受检者TgAb、TMAb及TSH水平,分析其临床意义.结果 三组间TgAb、TMAb和TSH水平存在明显差异,且A组TgAb、TMAb和TSH水平明显高于B组和对照组(P<0.05);A组TgAb、TMAb和TSH水平检测阳性率明显高于B组和对照组,B组TgAb、TMAb和TSH水平检测阳性率明显高于对照组(P<0.05);淋巴结有转移组TgAb和TSH水平明显高于对照组(P<0.05).结论 血清TgAb、TMAb和TSH水平升高可为甲状腺癌诊断提供参考,同时TSH、TgAb水平升高与甲状腺癌淋巴结转移密切相关.

摘要： 目的 探讨初诊桥本甲状腺炎(HT)患者的抗甲状腺微粒体抗体(TmAb)和抗甲状腺球蛋白抗体(TgAb)与甲状腺功能的相关性.方法 收集初诊甲状腺肿患者313例,其中HT患者132例,非HT患者181例,检测血清TmAb、TgAb、TSH、FT3、FT4、TT3、TT4及B超测定甲状腺大小,分析抗体与甲状腺功能的相关性.结果 HT患者年龄低于非HT患者,TSH高于非HT患者(P0.05),但FT3、FT4、TT3及TT4低于男性(P<0.05),非HT女性患者年龄、FT3及FT4低于男性患者(P<0.05);HT患者中TmAb与TSH呈正相关(P<0.05),与FT4呈负相关(P<0.05),TgAb与FT3、FT4及TT4呈负相关(P<0.05).结论 初诊HT患者自身抗体和性别与甲状腺功能存在密切关系,但抗体在甲状腺损伤过程中呈现不同作用特点.%To explore the relationships between TmAb, TgAb and thyroid function in the patients with newly-diagnosed Hashimoto's thyroiditis (HT). Mehtods The cases of goiter patients (n = 313) were collected, which included HT patients (n = 132) and non-HT patients (n = 181). Serum TmAb, TgAb, TSH, FT3, FT4, TT3 and TT4 of each patient were detected, and the sizes of thyroid gland were recorded through ultrosonography. The correlations of TmAb and TgAb with thyroid function were analyzed. Results Compared with the non-HT group, the patients' age was younger, and the TSH level was higher in the HT group (P < 0.05). The levels of TSH, TmAb and TgAb in the female HT patients were comparable to those in the male HT patients. However, the levels of FT3, FT4, TT3 and TT4 in the female HT patients were lower than those in the male HT patients (P < 0.05). The levels of FT3 and FT4 in the female non-HT patients were lower than those in the male non-HT patients, and their age was younger than that in the male non-HT patients (P < 0.05). Pearson correlation analysis showed that TmAb was positively correlated with TSH, and negatively correlated with FT4 in the patients with HT (P < 0.05); TgAb was negatively correlated with FT3, FT4 and TT4 (P < 0.05). Conclusions In newly-diagnosed HT patients, TmAb, TgAb and gender are closely correlated with the function of thyroid and these two antibodies indicate different patterns in thyroid damage.

摘要： 目的 探讨血清甲状腺球蛋白抗体(TGAb)、甲状腺微粒体抗体(TMAb)、甲状腺过氧化物酶抗体(TPOAb)水平与Graves病患者治疗后甲状腺功能减退(简称甲减)发生率的关系.方法 选取2014年5月至2015年6月在该院接收治疗的Graves病患者90例作为研究对象,对所有的患者进行分组,按照患者的TGAb、TPOAb水平分为阳性组(观察组)和阴性组(对照组),分别对患者在接受治疗前后的TGAb、TMAb、TPOAb水平,以及甲减发生率进行比较和分析.结果 观察组患者治疗前与治疗后的TGAb、TPOAb水平比较,差异无统计学意义(P>0.05),对照组患者在治疗后TGAb、TPOAb水平与治疗前相比明显升高,差异有统计学意义(P0.05);对照组患者的早发甲减发生率为22.50%,观察组患者为48.00%,组间比较,差异有统计学意义(P0 .05);the TGAb and TPOAb levels after treatment in the control group were significantly increased compared with before treatment ,the difference was statistically signifi-cant(P0 .05);the occur-rence rate of early onset hypothyroidism was 22 .50% in the control group and which of hypothyroidism in the observation group was 48 .00% ,the difference was statistically significant(P<0 .05) .With the TSH level as the dependent variable and TGAb ,TPO-Ab and TMAb as the independent variables after treatment in the patients with hypothyroidism ,the linear correlation analysis was performed ,the results showed that the TSH level in the patients with hypothyroidism was significantly correlated with TGAb and TPOAb (r=0 .401 ,0 .456 ,P< 0 .05) .Conclusion The detection of thyroid autoantibodies before treatment in the patients with Graves disease has a positive guiding significance for the treatment of patients .For positive patients ,the dosage of 131 I should appro-priate to reduce according to the specific circumstances of the patients to avoid the hypothyroidism occurrence ;for negative patients , whether the increase of TPOAb and TGAb levels being related with the low incidence rate of hypothyroidism or hyperthyroidism recurrence need to be further researched .

摘要： Objective To investigate the clinical efficacy of Xiaojin Tablets combined with methylprednisolone in treatment of subacute thyroiditis. Methods Patients (312 cases) with subacute thyroiditis in Guangzhou Panyu District Hospital of Traditional Chinese Medicine from April 2015 to April 2017 were divided into control (156 cases) and treatment (156 cases) groups according to different treatments. Patients in the control group were po administered with Methylprednisolone Tablets, the initial dose was 24 mg/d, and 16 mg/d after 2 weeks, 8 mg/d after 4 weeks, 4 mg/d after 6 weeks. Patients in the treatment group were po administered with Xiaojin Tablets on the basis of the control group, 0.72 g/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the improvement of clinical symptoms and serological indexes in two groups before and after treatment was compared. Results After treatment, clinical efficacy in the control group was 82.05%, which were significantly lower than 92.31% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the disappearance time of pharyngodynia, thyroid pain, thyroid nodule and fever in the treatment group were significantly shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the CRP, ESR, TGAb, TPOAb and TRAb levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the serological indexes after treatment in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xiaojin Tablets combined with methylprednisolone can effectively improve the clinical symptoms and inflammatory state in treatment of subacute thyroiditis, which is conducive to the recovery of impaired thyroid function and has a certain clinical application value.%目的 探讨小金片联合甲泼尼龙片治疗亚急性甲状腺炎的临床疗效.方法 选取2015年4月—2017年4月在广州市番禺区中医院进行诊治的亚急性甲状腺炎患者312例,根据用药的差别分为对照组(156例)和治疗组(156例).对照组口服甲泼尼龙片,初始剂量24 mg/d,2周后16 mg/d,4周后8 mg/d,6周后4 mg/d.治疗组在对照组的基础上口服小金片,0.72 g/次,2次/d.两组患者均治疗8周.观察两组患者临床疗效,比较治疗前后两组患者临床症状和血清学指标改善情况.结果 治疗后,对照组的临床有效率为82.05%,显著低于治疗组的92.31%,两组比较差异具有统计学意义(P<0.05).治疗后,治疗组咽痛、甲状腺疼痛和甲状腺肿块消失时间以及退热时间均明显短于对照组患者,两组比较差异具有统计学意义(P<0.05).治疗后,两组患者血清C反应蛋白(CRP)、血沉、甲状腺球蛋白抗体(TGAb)、甲状腺微粒体抗体(TPOAb)和促甲状腺激素受体抗体(TRAb)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗后治疗组患者上述血清学指标明显低于对照组,两组比较差异具有统计学意义(P<0.05).结论 小金片联合甲泼尼龙片治疗亚急性甲状腺炎可有效改善患者临床症状和炎症状态,有利于恢复受损的甲状腺功能,具有一定的临床推广应用价值.

摘要： Objective To analyze the value of thyroglobulin antibodies (TGAb),thyroid microsomal antibody (TMAb) and antithyroid peroxidase antibody (TPOAb) in the diagnosis of hashimoto thyroiditis.Methods A total of 57 patients with suspected hashimoto thyroiditis were selected and 54 patients were diagnosed with hashimoto thyroiditis with clinical or pathological diagnosis as the gold standard.The TGAb,TMAb and TPOAb levels of all patients were detected to calculate the sensitivity,specificity and compliance of TGAb,TMAb and TPOAb levels in the diagnosis of hashimoto thyroiditis.Results The TGAb,TMAb and TPOAb levels of patients with hashimoto thyroiditis were significantly higher than the normal reference value (P ＜ 0.05);there were significant differences in the diagnosis sensitivity and coincidence rate among the three indexes (P ＜ 0.05),and the sensitivity and coincidence rate of TPOAb were the highest,but the specificity of TGAb was significantly higher than that of TPOAb and TMAb (P ＜ 0.05).Conclusion The detection of TPOAb and TGAb levels has high value in the diagnosis of hashimoto thyroiditis,but appropriate index should be selected according to specific circumstances to assist the diagnosis.For example,TPOAb with higher sensitivity is preferred for disease screening,while TGAb with higher specificity is preferred for clinical diagnosis.%目的 分析甲状腺球蛋白抗体(TGAb)、甲状腺微粒体抗体(TMAb)和抗甲状腺过氧化物酶抗体(TPOAb)在桥本甲状腺炎诊断中的价值.方法 选取疑似桥本甲状腺炎患者57例,以临床或病理诊断为金标准,确诊为桥本甲状腺炎的有54例.检测所有患者的TGAb、TMAb和TPOAb水平,计算TGAb、TMAb和TPOAb水平诊断桥本甲状腺炎的灵敏度、特异度和符合度.结果 桥本甲状腺炎患者的TGAb、TMAb和TPOAb水平均明显高于正常参考值(P＜0.05);3项指标诊断的灵敏度和符合率之间有显著差异(P＜0.05),其中以TPOAb的灵敏度和符合率最高,而TGAb的特异度明显高于TPOAb和TMAb(P＜0.05).结论 检测TPOAb和TGAb水平对桥本甲状腺炎的诊断具有较高的诊断价值,但应根据具体情况选择合适的指标辅助诊断,对于疾病筛查宜选择检测灵敏度较高的TPOAb,临床诊断上则宜选择检测特异度较高的TGAb.

摘要： 本发明涉及一种检测抗甲状腺过氧化物酶和甲状腺球蛋白的天然双特异性抗体的试剂盒，属于临床检验学领域。本发明通过对患者血清，疾病对照血清和健康对照血清进行检测发现，抗TPO和Tg的双特异性抗体在患者中的检出率明显高于对照组，并具有统计学意义。本发明的优点是：本发明所描述的试剂盒的检测方法提供了一种简单易行的双特异性抗体检测模式，可以推广应用于各种双特性抗体的检测。

摘要： 本发明公开了一种甲状腺过氧化物酶抗体(TPO-Ab)磁微粒化学发光免疫定量检测试剂盒，所述试剂盒包括：甲状腺过氧化物酶抗体校准品；偶联有链霉亲和素的磁微粒悬浮液；生物素标记的甲状腺过氧化物酶抗原；鼠抗人酶标结合物，所用的酶为辣根过氧化物酶，辣根过氧化物酶纯度RZ≥3.0，活性≥250U/mL；甲状腺过氧化物酶抗体质控品；化学发光液A液和B液；20倍浓缩洗液；反应管。另外本发明还公开了本发明试剂盒的制备方法。本发明试剂盒与现有试剂盒相比灵敏度高、可测定浓度范围宽、试剂有效期长、操作简单、检测自动化程度高等优点。

摘要： 本发明涉及一种人甲状腺球蛋白抗体（TGAb）的磁微粒化学发光免疫检测方法，属于免疫检测分析技术领域。异硫氰酸荧光素（FITC）标记的TG抗原和碱性磷酸酶（AP）标记的人IgG抗体结合，形成抗原-抗体-酶标二抗的夹心免疫复合物，类似“三明治”结构。随后加入连有抗FITC抗体的磁性微粒，通过抗FITC抗体与FITC的特异性结合使抗原抗体复合物连接在磁颗粒上，在外加磁场中直接沉淀，不需离心即可将免疫反应形成的复合物与未结合的其它物质分离。本发明试剂盒将化学发光与磁微粒相结合，提供了一种接近均相的反应体系，与现有技术相比，本发明试剂盒具有更高的灵敏度、线性范围宽、快速等诸多优点，并且大大降低了产品成本，在临床检验等方面具有广阔的应用前景。

摘要： 本发明试剂盒涉及一种人甲状腺过氧化物酶抗体（TPOAb）的磁微粒化学发光免疫检测方法，属于免疫检测分析技术领域。异硫氰酸荧光素（FITC）标记的TPO抗原和碱性磷酸酶（AP）标记的人IgG抗体结合，形成抗原-抗体-酶标二抗的夹心免疫复合物，类似“三明治”结构。随后加入连有抗FITC抗体的磁性微粒，通过抗FITC抗体与FITC的特异性结合使抗原抗体复合物连接在磁颗粒上，在外加磁场中直接沉淀，不需离心即可将免疫反应形成的复合物与未结合的其它物质分离。本发明试剂盒将化学发光与磁微粒相结合，提供了一种接近均相的反应体系，具有更高的灵敏度、线性范围宽、快速等诸多优点，并降低了产品成本，在临床检验等方面具有广阔的应用前景。

摘要： 本发明提供了一种人促甲状腺激素受体抗体定量检测试剂盒，包括：包被有抗TSHR单克隆抗体A的固相载体；抗原试剂，所述抗原试剂为抗TSHR单克隆抗体B和TSHR的免疫复合物；含有标记物标记的人刺激性促甲状腺激素受体抗体；所述抗TSHR单克隆抗体A与抗TSHR单克隆抗体B不产生竞争性结合。本发明提供的试剂盒采用竞争法反应原理检测血清或血浆中促甲状腺激素受体抗体的浓度，试剂盒较为稳定，且能够避免生物素或荧光素钠的干扰，制备工艺更简单稳定，重复性良好，在提高产品性能的同时，大大降低了成本。

摘要： 本发明涉及一种检测抗甲状腺过氧化物酶和甲状腺球蛋白的天然双特异性抗体的试剂盒，属于临床检验学领域。本发明通过对患者血清，疾病对照血清和健康对照血清进行检测发现，抗TPO和Tg的双特异性抗体在患者中的检出率明显高于对照组，并具有统计学意义。本发明的优点是：本发明所描述的试剂盒的检测方法提供了一种简单易行的双特异性抗体检测模式，可以推广应用于各种双特性抗体的检测。

摘要： 本发明系用小鼠甲状腺球蛋白检测人血中抗甲状腺球蛋白抗体。该发明的特点是利用具有相同或相似生物学功能的生物大分子必然有相同或相似的分子结构，人甲状腺球蛋白(人TG)与小鼠甲状腺球蛋白(鼠TG)有着相同的生物活性，实验证明，人TG和鼠TG有抗原交叉性存在。本发明设计采用了固化绵羊血球标记小鼠TG，检测人血中的抗甲状腺球蛋白抗体，所制备的检测试剂可大大降低检测中的假阳性反应，检测成本低，快速、使用方便。

摘要： 本发明提供的是一种新颖和有用的方法，用于评估化合物或试剂降低微粒体前列腺素E合酶或造血前列腺素D合酶产生其相应前列腺素产物之活性的能力。

摘要： 本发明提供了一种用于检测甲状腺微粒体抗体的化学发光免疫检测试剂盒及其制备方法，所述试剂盒包括标记有示踪标记物的蛋白A抗原或标记有示踪标记物的抗人IgG和抗人IgM，以及包被磁球的甲状腺微粒体抗原或包被磁球的甲状腺微粒体抗原与蛋白载体的连接物。本发明还提供了甲状腺微粒体抗体浓度的检测方法。采用本发明提供的试剂盒对甲状腺微粒体抗体浓度进行检测，不涉及酶促反应，不需要通过酶来搭桥，因此试剂保存时间长，稳定；还可以借助全自动化学发光法进行检测，减少操作时间，降低人为操作误差，同时利用化学示踪标记物的特异性，提高检测灵敏度和准确性。

摘要： 本发明提供了一种用于检测甲状腺微粒体抗体的化学发光免疫检测试剂盒及其制备方法，所述试剂盒包括标记有示踪标记物的蛋白A抗原或标记有示踪标记物的抗人IgG和抗人IgM，以及包被磁球的甲状腺微粒体抗原或包被磁球的甲状腺微粒体抗原与蛋白载体的连接物。本发明还提供了甲状腺微粒体抗体浓度的检测方法。采用本发明提供的试剂盒对甲状腺微粒体抗体浓度进行检测，不涉及酶促反应，不需要通过酶来搭桥，因此试剂保存时间长，稳定；还可以借助全自动化学发光法进行检测，减少操作时间，降低人为操作误差，同时利用化学示踪标记物的特异性，提高检测灵敏度和准确性。